Amylin Pharmaceuticals, Inc presented detailed data from a 16-week Phase 2 obesity study of pramlintide (AC137) at the European Congress on Obesity (ECO) in Athens, Greece.

Pramlintide is a synthetic analog of human amylin, a hormone known to play a role in the regulation of appetite and food intake. It is the same compound as SYMLIN, Amylin’s lead drug candidate for type 1 and insulin-using type 2 diabetes.  Pramlintide has been studied extensively in people with diabetes and has demonstrated a chronic effect of lowering body weight. 

“The study showed statistically significant, progressive weight loss of 3.6 percent (3.5 kilograms) compared to placebo, with no evidence of a plateau in effect at 16 weeks. The weight loss was accompanied by a significant, progressive reduction in waist circumference, a recognized marker of abdominal obesity and cardiovascular risk.”

“It is clear that islet hormones can have important effects on satiety and food intake,” said Jeffrey Friedman, MD, PhD, Professor, Rockefeller University and Investigator, Howard Hughes Medical Institute.

Amylin submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration for the pramlintide obesity program earlier this year.

Reference - Medical News Today, Amylin

Powered by MightyAdsense

This entry was posted on Saturday, June 4th, 2005 at 4:16 pm and is filed under Health News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.